AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAK-671;AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-671;Ceoi: Serum Concentration at the end of Infusion for TAK-671;Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs);Number of Participants With Adverse Events (AEs) Related to Physical Examination Findings;Number of Participants With Markedly Abnormal 12-lead Electrocardiograms;Number of Participants With Markedly Abnormal Laboratory Values;Number of Participants With Markedly Abnormal Values of Vital Signs;T1/2z: Terminal Disposition Serum Half-life for TAK-671

AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAK-671;AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-671;Ceoi: Serum Concentration at the end of Infusion for TAK-671;Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs);Number of Participants With Adverse Events (AEs) Related to Physical Examination Findings;Number of Participants With Markedly Abnormal 12-lead Electrocardiograms;Number of Participants With Markedly Abnormal Laboratory Values;Number of Participants With Markedly Abnormal Values of Vital Signs;T1/2z: Terminal Disposition Serum Half-life for TAK-671